Emergent BioSolutions (EBS) announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain focused on driving long-term growth and profitability,” said Joe Papa, president and CEO of Emergent. “This announcement reflects our confidence in the company’s strategy, future outlook and cash generation and provides another avenue for us to create long-term value for shareholders, while delivering on our mission to protect and save lives.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent Biosolutions’ Strategic Investments and Divestitures Justify Buy Rating
- Hikma Pharmaceuticals announces Health Canada approval of KLOXXADO nasal spray
- Emergent BioSolutions announces $27M in incremental sales
- Emergent BioSolutions reinforces commitment to expanding access to NARCAN
- Emergent BioSolutions, Rocketvax announce investment agreement